Switch to:
More From Other Websites
[$$] Follow Up: Rival's Woes Bode Well for Sarepta Nov 28 2015
The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros Nov 27 2015
Why this company's $700 million bet could come up short Nov 25 2015
FDA Panel Seen As Bad For BioMarin, Good For Sarepta Nov 25 2015
Doubts about BioMarin drug Nov 25 2015
BioMarin's (BMRN) Kyndrisa Fails to Impress FDA Panel Nov 25 2015
BioMarin's Reversal of Fortune Nov 25 2015
Here’s what former Sarepta CEO Chris Garabedian had to say about BioMarin’s drug panel Nov 25 2015
BioMarin Pharma Crashed This Week, So Why Is This Mega-Bank Still Bullish? Nov 25 2015
Biotech Stock Roundup: KaloBios Soars as Shkreli Steps In, FDA Panel Not Convinced about BioMarin... Nov 25 2015
BioMarin: So You're Saying There's a Chance? Nov 25 2015
Early: DE, HRL, BXLT, TIVO, WMT, YHOO, TM & more Nov 25 2015
BioMarin's Duchenne Drug Is Done, Sarepta Survives but Faces Challenge Nov 25 2015
FDA Advisory Committee Discusses Clinical Data Package for BioMarin’s Kyndrisa(TM) (drisapersen)... Nov 24 2015
BioMarin Drug's Future In Doubt After FDA Panel Vote Nov 24 2015
FDA panel: BioMarin DMD drug data not persuasive enough Nov 24 2015
FDA panel raises concerns on BioMarin drug safety Nov 24 2015
FDA panel: BioMarin muscle wastage drug data not persuasive Nov 24 2015
BioMarin Gets Unfavorable View From Panel on Duchenne Drug Nov 24 2015

No Entry for this criteria! We are updating our databases daily, please come back later!

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership